Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS‐CoV‐2 neutralizing monoclonal antibody ABBV‐47D11 in patients with COVID‐19

• Главные авторы: Mohamad Shebley (Автор), Stanley Wang (Автор), Izna Ali (Автор), Preethi Krishnan (Автор), Rakesh Tripathi (Автор), Joseph M. Reardon (Автор), John Cafardi (Автор), Galia Rahav (Автор), Yoseph Caraco (Автор), Jihad Slim (Автор), Fadi Al Akhrass (Автор), Mengjia Yu (Автор), Yiran Hu (Автор), Rosa De Abreu Ferreira (Автор), Negar N. Alami (Автор)
• Формат: ‌
• Опубликовано: Wiley, 2023-02-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Abstract ABBV‐47D11 is a neutralizing monoclonal antibody that targets a mutationally conserved hydrophobic pocket distal to the ACE2 binding site of SARS‐CoV‐2. This first‐in‐human safety, pharmacokinetics, and antiviral pharmacodynamic assessment in patients with COVID‐19 provide an initial evalua...